儿童霍奇金淋巴瘤风险适应治疗对长期疾病风险的影响:儿童癌症幸存者研究
该研究评估了2996例1970至1999年诊断的儿童霍奇金淋巴瘤5年幸存者,采用自报严重慢性病、医学确认的后继恶性肿瘤及国家死亡指数死因,分析严重至致命慢性病(3-5级)累积发生率。35岁时任何3-5级病症累积发生率为31.4%,女性风险为男性2倍,从1970年代至1990年代每十年风险降低20%,低中危现代方案较高剂量扩大野放疗联合化疗预计降低40%风险。
要点
- 35岁时任何3-5级慢性病累积发生率为31.4%(95%CI 29.2-33.5)。
- 女性发生3-5级病症风险为男性2倍(HR 2.1,95%CI 1.8-2.4)。
- 低中危现代方案较高剂量胸部放疗联合化疗预计降低40%风险(HR 0.6,95%CI 0.4-0.8)。
核心结论
- 儿童霍奇金淋巴瘤的风险适应治疗显著降低了严重长期结局风险。
研究设计与样本
- 儿童癌症幸存者研究纳入2996例1970至1999年诊断的5年霍奇金淋巴瘤幸存者。
- 采用自报严重慢性病、医学确认的后继恶性肿瘤及国家死亡指数死因评估3-5级慢性病。
- 使用多变量回归模型估计每十年及关键治疗暴露的风险比(HR)。
主要发现
- 幸存者平均年龄35.6岁(范围12-58岁)。
- 35岁时任何3-5级病症累积发生率为31.4%(95%CI 29.2-33.5)。
- 女性发生3-5级病症风险为男性2倍(HR 2.1,95%CI 1.8-2.4)。
- 复发和/或造血细胞移植幸存者3-5级病症风险显著升高,与高剂量扩大野放疗幸存者相似(HR 1.2,95%CI 0.9-1.5)。
临床怎么用
- 儿童霍奇金淋巴瘤幸存者应关注严重慢性病风险,尤其女性及接受复发/移植或高剂量扩大野放疗者。
- 风险适应治疗可降低长期严重疾病风险,支持现代低中危方案的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the incidence of serious chronic health conditions among survivors of pediatric Hodgkin lymphoma (HL), compare by era of therapy and by selected cancer therapies, and provide estimates of risks associated with contemporary therapy. METHODS: Assessing 2,996 5-year HL survivors in the Childhood Cancer Survivor Study diagnosed from 1970 to 1999, we examined the cumulative incidence of severe to fatal chronic conditions (grades 3-5) using self-report conditions, medically confirmed subsequent malignant neoplasms, and cause of death based on the National Death Index. We used multivariable regression models to estimate hazard ratios (HRs) per decade and by key treatment exposures. RESULTS: HL survivors were of a mean age of 35.6 years (range, 12-58 years). The cumulative incidence of any grade 3-5 condition by 35 years of age was 31.4% (95% CI, 29.2 to 33.5). Females were twice as likely (HR, 2.1; 95% CI, 1.8 to 2.4) to have a grade 3-5 condition compared with males. From the 1970s to the 1990s, there was a 20% reduction (HR, 0.8; 95% CI, 0.7 to 0.9) in decade-specific risk of a grade 3-5 condition (P trend = .002). In survivors who had a recurrence and/or hematopoietic cell transplant, the risk of a grade 3-5 condition was substantially elevated, similar to that of survivors treated with high-dose, extended-field radiotherapy (HR, 1.2; 95% CI, 0.9 to 1.5). Compared with survivors treated with chest radiotherapy ≥ 35 Gy in combination with an anthracycline or alkylator, a contemporary regimen for low-intermediate risk HL was estimated to lead to a 40% reduction in risk of a grade 3-5 condition (HR, 0.6; 95% CI, 0.4 to 0.8). CONCLUSION: This study demonstrates that risk-adapted therapy for pediatric HL has resulted in a significant reduction in serious long-term outcomes.
引用
- Oeffinger KC, Stratton KL, Hudson MM, et al. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2021. PMID: 33630659. doi:10.1200/JCO.20.01186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。